GSK plc (the ‘Company’)
Transaction notification
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
James Ford | |||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044 | |||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
$46.9482 |
326.441 |
||||
|
d) |
Aggregated information |
N/A (single transaction) | |||
|
Aggregated volume Price |
|||||
|
e) |
Date of the transaction |
2026-10-13 | |||
|
f) |
Place of the transaction |
New York Stock Exchange (XNYS) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Maya Martinez-Davis | |||
|
b) |
Position/status |
President, US | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044 | |||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
$46.9482 |
351.842 |
||||
|
d) |
Aggregated information |
N/A (single transaction) | |||
|
Aggregated volume Price |
|||||
|
e) |
Date of the transaction |
2026-10-13 | |||
|
f) |
Place of the transaction |
New York Stock Exchange (XNYS) | |||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) | ||||
|
a) |
Name |
Shobie Ramakrishnan | |||
|
b) |
Position/status |
Chief Digital and Technology Officer | |||
|
c) |
Initial notification/ amendment |
Initial notification | |||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name |
GSK plc | |||
|
b) |
LEI |
5493000HZTVUYLO1D793 | |||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044 | |||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 | |||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
$46.9482 |
724.875 |
||||
|
d) |
Aggregated information |
N/A (single transaction) | |||
|
Aggregated volume Price |
|||||
|
e) |
Date of the transaction |
2026-10-13 | |||
|
f) |
Place of the transaction |
New York Stock Exchange (XNYS) | |||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.